Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies

Abstract

This study evaluated whether IgG anticardiolipinantibody (aCL) titre and traditional risk factors for atherosclerosis bore any relationship to the intima media thickness (IMT) of carotid arteries of patients with idiopathic antiphospholipid antibodies (aPL). IMT was assessed by high-resolution sonography at the common carotid, carotid bifurcation and internal carotid in 42 (13 male, 29 female, mean age 31§ 10 years) aPL subjects, 29 with primary thrombotic antiphospholipid syndrome and 13 with persistence of aPL in the absence of any underlying disorder. In the same subjects the following were measured: plasma fibrinogen (FNG), von Willebrand factor (vWF), plasminogen activator inhibitor (PAI), homocysteine (HC), total cholesterol (CHO), triglycerides (TG), high density and low density lipoprotein (HDL and LDL), platelet numbers and aCL of IgG and IgM isotype. IMT of the internal carotid was greater in males than females (0.48±0.03 vs 0.39±0.01 mm, P = 0.02). IMT of the carotid bifurcation was greater in thrombotic than nonthrombotic subjects (0.50§ 0.02 vs 0.42§ 0.02 mm, P = 0.04). By simple regression, IMT of the common carotids correlated with age (P < 0.0001) IgG aCL titre (P = 0.001), FNG (P = 0.006), LDL (0.01), CHO (0.02) and PAI (P = 0.02). IMT of the carotid bifurcation correlated with age (P = 0.002), IgG aCL titre (P = 0.0002), FNG (P = 0.0001), HC (P = 0.009), CHO (P = 0.02), vWF (P = 0.01) and number of thrombotic events (P = 0.03). IMT of the internal carotids correlated with age (P = 0.002), IgG aCL titre (P = 0.0001), FNG (P = 0.0008), PAI (P = 0.002) and HC (P = 0.01). By stepwise multiple regression analysis, IgG aCL titre independently predicted IMT at all carotid segments examined (P always < 0.005). In addition, plasma FNG and HC also resulted independent predictors of IMT at the carotid bifurcation (P = 0.001 and P < 0.0001, respectively) and internal carotid (P = 0.03 and P < 0.0001, respectively). These data strongly support an atherogenic role for IgG aCL in patients with aPL. Measurement of plasma HC and FNG may help define aPL subjects at higher vascular risk who may require lowering of HC and FNG by vitamin and/or pharmacologic intervention. Lupus (2002) 11, 208–214.

Keywords

anticardiolipin antibody homocysteine fibrinogen intima media thickness athero-sclerosis

Get full access to this article

View all access options for this article.

References

Finazzi G , Brancaccio V , Moia M et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four year prospective study from the Italian Registry . Am J Med 1996; 100: 530–536 .

McCarty GA , 2000. Vascular pathology of the antiphospholipid syndrome. In: Khamashta MA (ed). Hughes Syndrome (Antiphospholipid Syndrome). Springer, pp 263–280.

O'Leary DH , Polak JF , Krommal RA et al, on behalf of the CHF Collaborative Research Group. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study . Stroke 1992; 23: 1752–1760 .

Heiss G , Sharrett AR , Barnes R , Chambless LE , Szklo M , Alzola C for the ARIC investigators . Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factor in the ARIC study . Am J Epidemiol 1991; 134: 250–256 .

Salonen JT , Salonen R . Ultrasonographically assessed carotid morphology and the risk of coronary heart disease . Arterioscler Thromb 1991; 11: 1245–1249 .

Roman MJ , Salmon JE , Sobel R et al. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome . Am J Cardiol 2001; 87: 663–666, A11-A11

Glueck CJ , Lang JE , Tracy T , Sieve-Smith L , Wang P . Evidence that anticardiolipin antibodies are independent risk factors for atherosclerotic vascular disease . Am J Cardiol 1999; 83: 1490–1494 .

Nityanand S , Bergmark C , de Faire U , Swedenborg J , Holm G , Lefvert AK . Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease . J Intern Med 1995; 238: 437–443 .

Greaves M , Cohen H , Machin SJ , Mackie I Guidelines on the investigation and management of the antiphospholipid syndrome . Br J Haematol 2000; 109: 704–711 .

10.

Brancaccio V , Ames PRJ , Glynn J , Iannaccone L , Mackie IJ . A rapid screen for lupus anticoagulant (LA) by comparing a sensitive and insensitive aPTT reagent provides also good discrimination from oral anticoagulants, congenital factor deficiency and heparin . Blood Coagul Fibrinol 1997; 8: 155–160 .

11.

Manzi S , Meilahn EN , Rairie JE et al. Age-specific rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study . Am J Epidemiol 1997; 145: 408–415 .

12.

Ames PRJ . Medical Perspective. Antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus. A unifying ‘membrane stress syndrome’ hypothesis . Lupus 1994; 3: 371–377 .

13.

Manzi S , Selzer F , Sutton-Tyrrell K et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus . Arthritis Rheum 1999; 42: 51–60 .

14.

Lindsey NJ , Dawson RA , Henderson FI , Greaves M , Hughes P . Stimulation of von Willebrand factor antigen release by immunoglobulins from thrombosis prone patients with systemic lupus erythematosus and the primary antiphospholipid syndrome . Br J Rheumatol 1993; 32: 123–126 .

15.

Amengual O , Atusmi T , Khamashta MA , Hughes GRV . The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome . Thromb Haemost 1998; 79: 276–281 .

16.

Simantov R , Activation of cultured vascular endothelial cells by antiphospholipid antibodies . J Clin Invest 1995; 96: 2211–2219 .

17.

Ames PRJ , Iannaccone L , Tommasino C , Brillante M , Cimino R , Brancaccio V . Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies. A crucial role for acquired free protein S deficiency . Thromb Haemost 1996; 76: 190–194 .

18.

Ames PRJ , Pyke S , Iannaccone L , Brancaccio V . Antiphospholipid antibodies, haemostatic variables and thrombosis. A survey of 144 patients . Thromb Haemostas 1995; 73: 768–775 .

19.

Kaplanski G , Cacoub P , Farnarier C et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlation with the severity of thrombosis . Arthritis Rheum 2000; 43: 55–64 .

20.

De Stefano V , Casorelli I , Rossi E , Zappacosta B , Leone G . Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism . Sem Thromb Hemost 2000; 26: 305–311 .

21.

Cappucci C , Margaglione M , Ames PRJ . Comparative prevalence of antiphospholipid antibodies and thrombophilic genotypes in consecutive patients with venous thrombosis . Blood Coagul Fibrinol 2001; 12: 659–665 .

22.

Ames PRJ , Tommasino C , Margaglione M , Bossone A , Iannaccone L , Brancaccio V . Relevance of plasma homocysteine and thrombophilic genotypes in primary antiphospholipidsyndrome . Blood Coagul Fibrinol 2001; 12: 699–704 .

23.

Selhub J , Jacques PF , Bostom A et al. Association between plasma homocysteine concentrations and extracranial carotid artery stenosis . New Engl J Med 1995; 332: 286–291 .

24.

Voutilainen S , Alfthan G , Nyyssonen K , Salonen R , Salonen JT . Association between elevated plasma total homocysteine and increased common carotid artery wall thickness . Ann Med 1998; 30: 300–306 .

25.

Willinek WA , Ludwig M , Lennarz M , Holler T , Stumpe KO . High-normal serum homocysteine concentrations are associated with an increased risk of early atherosclerotic carotid artery wall lesions in healthy subjects . J Hypertens 2000; 18: 425–430 .

26.

Fryer RH , Wilson BD , Gubler DB , Fitzgerald LA , Rodgers GM . Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells . Arterioscler Thromb Vasc Biol 1993; 13: 1327–1333 .

27.

Midorikawa S , Sanada H , Hashimoto S , Watanabe T . Enhancement by homocysteine of plasminogen activator inhibitor-1 gene expression and secretion from vascular endothelial and smooth muscle cells . Biochem Biophys Res Commun 2000; 272: 182–185 .

28.

de Valk-de Roo GW , Stehouwer CD , Lambert J et al. Plasma homocysteine is weakly correlated with plasma endothelin and von Willebrand factor but not with endothelium-dependent vasodilatation in healthy postmenopausal women . Clin Chem 1999; 45: 1200–1205 .

29.

Gottsater A , Anwaar I , Eriksson KF , Mattiasson I , Lindgarde F . Homocysteine is related to neopterin and endothelin-1 in plasma of subjects with disturbed glucose metabolism and reference subjects . Angiology 2000; 51: 489–497 .

30.

Becker A , Van Hinsbergh VW , Kostense PJ et al. Serum homocysteine is weakly associated with von Willebrand factor and soluble vascular cell adhesion molecule 1, but not with C-reactive protein in type 2 diabetic and non-diabetic subjects—the Hoorn study . Eur J Clin Invest 2000; 30: 763–770 .

31.

Atsumi T , Khamashta MA , Haworth RS et al. Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin-1 . Arthritis Rheum 1998; 41: 800–807 .

32.

Williams FM , Parmar K , Hughes GR , Hunt BJ . Systemic endothelial cell markers in primary antiphospholipid syndrome . Thromb Haemost 2000; 84: 742–746 .

33.

Voutilainen S , Morrow JD , Roberts LJ Jr et al. Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels . Arterioscler Thromb Vasc Biol 1999; 19: 1263–1266 .

34.

Ames PRJ , Nourooz-Zadeh J , Tommasino C , Alves J , Brancaccio V , Anggard EE . ‘Oxidative stress’ in primary antiphospholipidsyndrome . Thromb Haemost 1998; 79: 447–449 .

35.

Halliwell B . Oxidation of low-density lipoproteins: questions of initiation, propagation, and the effect of antioxidants . Am J Clin Nutr 1995; 61: 670S–677S .

36.

Maresca G , Di Blasio A , Marchioli R , Di Minno G . Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update . Arterioscler Thromb Vasc Biol 1999; 19: 1368–1377 .

37.

Lee AJ , Mowbray PI , Lowe GD , Rumley A , Fowkes FG , Allan PL . Blood viscosity and elevated carotid intima-media thickness in men and women: the Edinburgh Artery Study . Circulation 1998; 97: 1467–1473

38.

Smith EB , Thomson WD . Fibrin as a factor in atherogenesis . Thromb Res 1994; 73: 1–19 .

39.

Ribes JA , Francis CW , Wagner DD . Fibrin induces release of von Willebrand factor from endothelial cells . J Clin Invest 1987; 79: 117–123 .

40.

Sironi M , Breviario F , Proserpio P et al. IL-1 stimulated IL-6 production in endothelial cells . J Immunol 1989; 142: 549–556 .